Relationship between the production of autoantibodies to oxidized low-density lipoprotein and hepatic steatosis in patients with chronic hepatitis C

Himoto,Takashi; Yoneyama,Hirohito; Deguchi,Akihiro; Kurokohchi,Kazutaka; Inukai,Michio; Masugata,Hisashi; Goda,Fuminori; Senda,Shoichi; Haba,Reiji; Watanabe,Seishiro; Nishioka,Mikio; Masaki,Tsutomu

doi:10.3892/etm_00000104

Relationship between the production of autoantibodies to oxidized low-density lipoprotein and hepatic steatosis in patients with chronic hepatitis C

Authors:
- Takashi Himoto
- Hirohito Yoneyama
- Akihiro Deguchi
- Kazutaka Kurokohchi
- Michio Inukai
- Hisashi Masugata
- Fuminori Goda
- Shoichi Senda
- Reiji Haba
- Seishiro Watanabe
- Mikio Nishioka
- Tsutomu Masaki
View Affiliations

Affiliations: Department of Integrated Medicine, Kagawa University School of Medicine, Kita-Gun, Kagawa 761-0793, Japan. thimoto@med.kagawa-u.ac.jp
Published online on: July 1, 2010 https://doi.org/10.3892/etm_00000104
Pages: 663-668

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Persistent hepatitis C virus (HCV) infection induces oxidative stress and eventually leads to hepatic steatosis. Oxidatively modified autoantigens, including oxidized low-density lipoprotein (ox-LDL), were identified in patients with systemic lupus erythematosus. Chronic HCV infection often evokes autoimmune phenomena, such as autoantibody production and/or concurrent autoimmune diseases. We examined the relationship between the production of antibodies to ox-LDL (anti-ox-LDL) and hepatic steatosis in patients with chronic hepatitis C (CH-C). Anti-ox-LDL levels were determined by the enzyme-linked immunosorbent assay method. The severity of hepatic steatosis was evaluated using the classification proposed by Brunt and colleagues. The effect of antiviral treatment was also investigated. Twenty-two (52%) of the 42 patients with CH-C had no hepatic steatosis (grade 0), while 12 (29%) and 8 (19%) had grade 1 and 2 hepatic steatosis, respectively. The overall serum immunoglobulin G (IgG) level in patients with grade 2 steatosis was significantly higher than that in patients with grade 0 steatosis (1,999±340 vs. 1,465±196 mg/dl, p<0.0001). The mean anti-ox-LDL level in grade 2 steatosis patients was also higher than that in grade 0 steatosis patients (754±479 vs. 361±274 mU/ml, p=0.0165). A close correlation was apparent between anti-ox-LDL and serum IgG levels (r=0.390, p=0.0107). There was no significant difference in the level of anti-ox-LDL between CH-C patients who acquired sustained virological response (SVR) and those who exhibited non-SVR. These findings suggest that anti-ox-LDL in patients with CH-C is induced in the process of hepatic steatosis and that the emergence of anti-ox-LDL does not affect antiviral treatment.

View Figures

View References

1.	Koike K and Miyoshi H: Oxidative stress and hepatitis C viral infection. Hepatol Res. 34:65–73. 2006. View Article : Google Scholar : PubMed/NCBI
2.	Okuda M, Li K, Beard MR, et al: Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein. Gastroenterology. 122:366–375. 2002. View Article : Google Scholar : PubMed/NCBI
3.	Farinati F, Cardin R, De Maria N, et al: Iron storage, lipid peroxidation and glutathione turn over in chronic anti-HCV positive hepatitis. J Hepatol. 22:449–456. 1995. View Article : Google Scholar : PubMed/NCBI
4.	Lonardo A, Adinolfi LE, Loria P, et al: Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease. Gastroenterology. 126:588–597. 2004. View Article : Google Scholar : PubMed/NCBI
5.	Moriya K, Yotsuyanagi H, Shintani Y, et al: Hepatitis C virus core protein induces hepatic steatosis in transgenic mice. J Gen Virol. 78:1527–1531. 1997.PubMed/NCBI
6.	Devenyi P, Rutherdale J, Sereny G and Olin JS: Clinical diagnosis of alcoholic fatty liver. Am J Gastroenterol. 54:597–602. 1970.PubMed/NCBI
7.	Murthy VK and Shipp JC: Hepatic steatosis in diabetes: increased synthesis of triglycerol and impaired feedback regulation. Trans Assoc Am Physicians. 94:322–332. 1981.PubMed/NCBI
8.	Hill RB and Rude JFP: Cortisone-induced lipaemia and hepatic steatosis in the male rat. Nature. 210:7331966. View Article : Google Scholar : PubMed/NCBI
9.	Hourigan LF, Macdonald GA, Purdie D, et al: Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology. 29:1215–1219. 1999. View Article : Google Scholar : PubMed/NCBI
10.	Adinolfi LE, Gambardella M, Andreana A, Tripodi MF, Utili R and Ruggiero G: Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology. 33:1358–1364. 2001. View Article : Google Scholar : PubMed/NCBI
11.	Monto A, Alonzo J, Watson JJ, Grunfeld C and Wright TL: Steatosis in chronic hepatitis C: relative contribution of obesity, diabetes mellitus, and alcohol. Hepatology. 36:729–736. 2002. View Article : Google Scholar : PubMed/NCBI
12.	Hui JM, Kench J, Farrell GC, et al: Genotype-specific mechanisms for hepatic steatosis in chronic hepatitis C infection. J Gastroenterol Hepatol. 17:873–881. 2002. View Article : Google Scholar : PubMed/NCBI
13.	Poynard T, Ratziu V, McHutchison J, et al: Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology. 38:75–85. 2003. View Article : Google Scholar : PubMed/NCBI
14.	Fartoux L, Poujol-Robert A, Guechot J, Wendum D, Poupon R and Serfaty L: Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C. Gut. 54:1003–1008. 2005. View Article : Google Scholar : PubMed/NCBI
15.	Camma C, Bruno S, Marco VD, et al: Insulin resistance is associated with steatosis in nondiabetic patients with genotype 1 chronic hepatitis C. Hepatology. 43:64–71. 2006. View Article : Google Scholar : PubMed/NCBI
16.	Soresi M, Tripi S, Franco V, et al: Impact of liver steatosis on the antiviral response in hepatitis C virus-associated chronic hepatitis. Liver Int. 26:1119–1125. 2006. View Article : Google Scholar : PubMed/NCBI
17.	Westin J, Lagging M, Dhillon AP, et al: Impact of hepatic steatosis on viral kinetics and treatment outcome during antiviral treatment of chronic HCV infection. J Viral Hepat. 14:29–35. 2007. View Article : Google Scholar : PubMed/NCBI
18.	Ohta K, Hamasaki K, Toriyama K, et al: Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C virus infection. Cancer. 97:3036–3043. 2003. View Article : Google Scholar : PubMed/NCBI
19.	Kumar D, Farrell GC, Kench J and George J: Hepatic steatosis and the risk of hepatocellular carcinoma in chronic hepatitis C. J Gastroenterol Hepatol. 20:1395–1400. 2005. View Article : Google Scholar : PubMed/NCBI
20.	Pawlotsky JM, Yahia MB, Andre C, et al: Immunological disorders in C virus chronic active hepatitis: a prospective case-control study. Hepatology. 19:841–848. 1994. View Article : Google Scholar : PubMed/NCBI
21.	Manns MP and Rambusch EG: Autoimmunity and extrahepatic manifestations in hepatitis C virus infection. J Hepatol. 31:S39–S42. 1999. View Article : Google Scholar : PubMed/NCBI
22.	Vaarala O, Alfthan G, Jauhiainen M, et al: Crossreaction between antibodies to oxidized low-density lipoprotein and to cardiolipin in systemic lupus erythematosus. Lancet. 341:923–925. 1993. View Article : Google Scholar : PubMed/NCBI
23.	Hsu RM, Devaraj S and Jialal I: Autoantibodies to oxidized low-density lipoprotein in patients with type 2 diabetes mellitus. Clin Chim Acta. 317:145–150. 2002. View Article : Google Scholar : PubMed/NCBI
24.	Lau JY, Davis GL, Kinffen J, et al: Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lancet. 341:1501–1504. 1993. View Article : Google Scholar : PubMed/NCBI
25.	Simmonds P, Alberti A, Alter HJ, et al: A proposed system for nomenclature of hepatitis C viral genotypes. Hepatology. 19:1321–1324. 1994. View Article : Google Scholar : PubMed/NCBI
26.	Brunt EM, Janney CG and Bisceglie D: Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol. 94:2467–2474. 1999. View Article : Google Scholar : PubMed/NCBI
27.	Ichida F, Tsuji T, Omata M, et al: New Inuyama classification: new criteria for histological assessment of chronic hepatitis. Int Hepatol Commun. 6:112–119. 1996. View Article : Google Scholar
28.	Knodel RG, Ishak KG, Black WC, et al: Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology. 1:431–435. 1981. View Article : Google Scholar
29.	Becarevic M, Singh S and Majkic-Singh N: Oxidized LDL, anti-oxidized LDL and anti-annexin A5 antibodies in primary antiphospholipid syndrome. Clin Lab. 54:97–101. 2008.PubMed/NCBI
30.	Shoji T, Nishizawa Y, Fukumoto M, et al: Inverse relationship between circulating oxidized low-density lipoprotein (oxLDL) and anti-oxLDL antibody levels in healthy subjects. Atherosclerosis. 148:171–177. 2000. View Article : Google Scholar : PubMed/NCBI
31.	Vidali M, Tripodi MF, Ivaldi A, et al: Interplay between oxidative stress and hepatic steatosis in the progression of chronic hepatitis C. J Hepatol. 48:399–406. 2008. View Article : Google Scholar : PubMed/NCBI
32.	Loria P, Lonardo A, Leonardi F, et al: Non-organ-specific autoantibodies in nonalcoholic fatty liver disease: prevalence and correlates. Dig Dis Sci. 48:2173–2181. 2003. View Article : Google Scholar : PubMed/NCBI
33.	Adams LA, Lindo KD and Angulo P: The prevalence of autoantibodies and autoimmune hepatitis in patients with nonalcoholic fatty liver disease. Am J Gastroenterol. 99:1316–1320. 2004. View Article : Google Scholar
34.	Czaja AJ, Carpenter HA, Santrach PJ and Moore SB: Host- and disease-specific factors affecting steatosis in chronic hepatitis C. J Hepatol. 29:198–206. 1998. View Article : Google Scholar : PubMed/NCBI
35.	Escarcega RO, Garcia-Carrasco M, Fuentes-Alexandro S, et al: Insulin resistance, chronic inflammatory state and the link with systemic lupus erythematosus-related coronary disease. Autoimmun Rev. 6:48–53. 2006. View Article : Google Scholar
36.	Gatselis NK, Georgiadou SP, Koukoulis GK, et al: Clinical significance of organ- and non-organ-specific autoantibodies on the response to anti-viral treatment of patients with chronic hepatitis C. Aliment Pharmacol Ther. 24:1563–1573. 2006. View Article : Google Scholar : PubMed/NCBI
37.	Wasmuth HE, Stolte C, Geier A, et al: The presence of non-organ-specific autoantibodies is associated with a negative response to combination therapy with interferon and ribavirin for chronic hepatitis C. BMC Infect Dis. 4:1–8. 2004. View Article : Google Scholar : PubMed/NCBI